Lundbeck’s Pipeline Clarity and Vyepti Momentum Steal the Show
Strong H1 growth, de-leveraging, and a maturing pipeline set the stage for a catalyst-rich 2026-27.
HLUN-B.CO · Earnings Call · 2026-08-19
A Growth Engine Running on All Cylinders
Lundbeck’s first half of 2026 delivered revenue growth of 16% at constant exchange rates, driven by the strategic brands Vyepti and Rexulti. As CEO Charl van Zyl put it, “we see now the full year guidance confirmed through this halfway point through 2026” — Charl van Zyl, CEO · 2026-08-19 — a reassuring sign after the upgrade in Q1. The commercial momentum is underpinned by Vyepti’s U.S. market share reaching an all-time high of 13.01%, as Thomas Gibbs highlighted: “Our monthly market share in the U.S. reached an all-time high of 13.01% compared to 11% at the beginning of 2026” — Thomas Gibbs, Executive Leadership Team Member · 2026-08-19. This is nearly triple the market growth rate, suggesting the brand continues to take share.Pipeline: From Promise to Proof
The real transformation is in the pipeline. The company is positioning itself for a wave of catalysts. Johan Luthman noted that the bexicaserin program has closed randomization in the DEEp OCEAN trial, “has in July, closed randomization in the DEEp OCEAN trial” — Johan Luthman, Executive Leadership Team Member / Head of R&D (retiring) · 2026-08-19. The orexin program received Fast Track designation from the FDA, and is being positioned as a potential best-in-class opportunity in daytime hypersomnolence disorders. The pivotal trial for amlenetug is on track for a H2 ’27 readout, and management expects the headline results for bexicaserin by the end of 2026. This is a significant maturation from just a year ago, when the pipeline was thinner and earlier-stage.Financial Discipline and Guidance
The company is confirming its upgraded guidance, with CFO Joerg Hornstein stating, “Following the strong H1 performance, we are maintaining those upgraded ranges at constant exchange rates” — Joerg Hornstein, CFO · 2026-08-19. Leverage has been cut to ~1x net debt/EBITDA after the Longboard acquisition, and R&D investment continues at a robust 24% growth rate in H1. The midterm guidance framework remains intact, though an update is expected around Q4. The partner market transition is a recurring theme from prior calls; partner market dynamics explain some of the reported volatility, but the underlying demand signals are strong. Competition in the schizophrenia/AD space remains a watch item, but the company has confidence in its differentiated profile. In the May 2026 call, CFO Joerg Hornstein attributed the guidance raise to “50% to Vyepti and 50% to the delayed generic entry” — Joerg Hornstein, Chief Financial Officer · 2026-05-13 — a transparency that continues to build trust.Strategic Positioning
Lundbeck is at an inflection point. With the R&D leadership transition from Johan Luthman to Tarek Samad, the company is poised to execute on a maturing pipeline. The CEO concluded,This encapsulates the narrative: a company that has rebuilt its commercial engine and now has the scientific firepower to sustain long-term growth.we are very confident as we go through the first half of the year and our full year guidance that we will have another strong year and of course, underpinned by strong growth and a very compelling pipeline with some near-term catalysts coming up very soon with bexicaserin.